SpectraCure presents results from Phase 1 study

SpectraCure presents results from the company's Phase 1 study at The 17th International Photodynamic Association World Congress in Boston.

SpectraCure (publ) will present results from the company's Phase 1 study at the International Photodynamic Association World Congress arranged June 28th - July 4th in Boston, Massachusetts, USA. The presentation will be held by Johannes Swartling, CTO.

- We look forward to presenting the results from the Phase 1 study at a world conference and it is very exciting to share the successful result from SpectraCure's Phase 1 study with world-leading clinical researchers, says Masoud Khayyami, CEO of SpectraCure.

The patient treatments in the Phase 1 study are completed, patient follow-up will be performed until all patients have undergone a biopsy one year after treatment.

SpectraCure initiated patient treatments in the following Phase 2 study together with its clinical partners during the month of April. The purpose of the Phase 2 study is to show that the method is safe to use and that it has clinical effect, with a larger statistical basis than in the Phase 1 study.

For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46-(8)-503 000 50.

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region

Tags:

About Us

SpectraCure's business concept is to, with its proprietary and patent-pending system, cure internal cancer tumors, prolong survival for cancer patients, and to act as complementary treatment options for other cancer treatments.

Subscribe

Documents & Links